Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Intervention1: Etomidate for Rapid sequence intubation: Etomidate at dose of 0.3 mg/kg as applicable given intravenously.
Control Intervention1: No Comparator: This is a single arm study
Sponsors
AIG Hospitals
Eligibility
Inclusion criteria
Inclusion criteria: -Patients receiving a single dose of etomidate as the induction agent for intubation -Patients who can provide informed consent or for whom consent can be obtained from a legally authorized representative
Exclusion criteria
Exclusion criteria: -Patients with known adrenal insufficiency or receiving chronic corticosteroid therapy - Patients with a recent history of etomidate exposure (Within 24 hours) - Patients with contraindications to Etomidate - Pregnant patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure and assess the decrease in serum cortisol levels compared to pre-intubation baseline at 30 minutes and 24 hours post intubationTimepoint: 0 minutes, 30 minutes and 24 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| all cause mortalityTimepoint: 48 hours | — |
Countries
India
Contacts
Public ContactDr Sarat Chandra Uppaluri
AIG Hospitals
Outcome results
None listed